Paul D. Maroni, MD

Articles

Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification

Tyler P. Robin, MD, PhD;Paul D. Maroni, MD;Bennett B. Chin, MD;Francisco G. La Rosa, MD;Brandon Bernard, MD, MPH;Thomas J. Pugh, MD

July 15th 2018

A 62-year-old man with prostate adenocarcinoma elected to proceed with radical prostatectomy as definitive management. After his pathology report showed stage IIIB disease, he elected for observation. What happened next?

Is Radical Prostatectomy Appropriate for Very-High-Risk Prostate Cancer Patients? Yes.

Paul D. Maroni, MD

May 15th 2015

At worst radical prostatectomy is equal to radiation therapy in operable very-high-risk prostate cancer, and there are accumulating data to suggest that a surgery-first approach is better induction for multimodal therapy.

Metastatic Relapse After Initial Clinical Stage I Testicular Leydig Cell Tumor

Nicholas G. Cost, MD;Paul D. Maroni, MD;Thomas W. Flaig, MD

March 15th 2014

A 70-year-old, otherwise healthy man presented to his primary care provider for an annual checkup, at which time a nontender right testicular mass was noted. He denied any symptoms, and his serum alpha-fetoprotein and beta-human chorionic gonadotropin levels were normal.

In Germ Cell Cancer, Are We at the End of the Chemotherapy Era? Maybe-and We Are Certainly at the End of the RCT Era

Paul D. Maroni, MD

November 15th 2013

Cisplatin-based chemotherapy has transformed the prognosis of testicular germ cell cancer (GCT). It has converted the chief mortal malignancy in younger men into a model for the curability of cancer.

Hopes and Dreams for Quality Improvement in Radical Prostatectomy

Paul D. Maroni, MD;Jason M. Phillips, MD

July 15th 2012

We fervently hope that all surgeons will participate in a comparative outcomes project for the purpose of quality improvement. However, today we will settle for one, we hope, skilled surgeon, open or robotic.

A Man With Changes in the Urinary Bladder: Benign Metaplasia or Adenocarcinoma?

Thomas W. Flaig, MD;Francisco G. La Rosa, MD;Kristen Mckinney, MD;Paul D. Maroni, MD;Shandra S. Wilson, MD

February 19th 2009

The patient is a 39-year-old man who presents with pelvic lymphadenopathy. He has a history of ureteral reflux disease, recurrent nephrolithiasis, right nephrectomy, ileal loop diversion of the left ureter, and radical cystectomy for “bladder cancer,” which he underwent 3 years ago. The lymphadenopathy was discovered incidentally during recent imaging.

The Challenge of Comparing Investigative Approaches to Prostate Cancer

Paul D. Maroni, MD;E. David Crawford, MD

July 1st 2008

The article by Polascik and coauthors provides a timely synopsis of modern technologic advances in prostate cryoablation and a review of the rationale for and experience with targeted prostate treatments. Prostate cryoablation has a storied past, which can be briefly summarized as high excitement followed by near-complete abandonment. Fortunately, a few practitioners improved the technique and incorporated new technologies allowing for its resurrection.